Naxitamab plus GM-CSF demonstrated strong antitumor activity and manageable toxicity in high-risk neuroblastoma patients, ...

Historically, there was no clear standard of care nor regulatory approvals for therapy for SMM prior to the AQUILA study. The ...

Sequential ICV and IV administration of CR7-GD2 CAR T-cell therapy showed improved tolerability over concurrent dosing in ...

The bispecific HER2-directed antibody-drug conjugate (ADC) TQB2102 has demonstrated robust antitumor activity and a positive ...

The 2025 American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida, begins on December 6. This year, ...

DS-1594b showed on-target biological activity but failed to achieve protocol-defined responses, leading to early trial termination. Differentiation syndrome occurred in 29.4% of patients, prompting ...

CLN-049, a novel FLT3/CD3 bispecific T-cell engager, has received fast track designation from the FDA for the treatment of ...

The FDA has approved pegfilgrastim-unne (Armlupeg) for the treatment of patients with nonmyeloid cancers undergoing treatment ...

During a live event, Thomas G. Martin, MD, discussed the importance of controlling disease and avoiding barriers to access so patients with multiple myeloma can receive CAR T-cell therapy.

Combined androgen blockade shows significant survival benefits over single-agent ADT in high-risk prostate cancer, as ...

The FDA has granted premarket approval (PMA) to the IsoPSA test, a novel, blood-based in vitro diagnostic kit designed to ...

Tovorafenib provides durable disease control in pediatric patients with relapsed or refractory low-grade glioma harboring ...